Status:

UNKNOWN

Study of External Neuromodulation to Improve Signs and Symptoms of Dry Eye in Visual Display Terminal Users

Lead Sponsor:

Olympic Ophthalmics, Inc.

Conditions:

Visual Display Users With Previously Undiagnosed Dry Eye

Eligibility:

All Genders

18-69 years

Phase:

NA

Brief Summary

Two study arms - sham and treatment; There will be a cross over of the sham group to the treatment group at day 15.

Detailed Description

This is a post market study. The active device will be the FDA cleared device used within its labeling. The sham group will receive an iTEAR device which looks identical to and makes noise similar to ...

Eligibility Criteria

Inclusion

  • \> 6hrs visual display terminal
  • OSDI \> 13
  • One of: SChirmer \< 10, One quadrant staining \> 2, or Meibomian Gland expression \<12

Exclusion

  • Opinion of investigator that subject not be in the study

Key Trial Info

Start Date :

February 17 2021

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 1 2021

Estimated Enrollment :

35 Patients enrolled

Trial Details

Trial ID

NCT04763018

Start Date

February 17 2021

End Date

June 1 2021

Last Update

February 21 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Fishman Vision

Palo Alto, California, United States, 94301

Study of External Neuromodulation to Improve Signs and Symptoms of Dry Eye in Visual Display Terminal Users | DecenTrialz